DVAX · As filed with the SEC
Dynavax Technologies balance sheet, by quarter
The statement as Dynavax Technologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets · USD thousands
| USD thousands | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 160,247 | 99,101 | 51,720 | 95,883 |
| Marketable securities available-for-sale | 487,568 | 514,628 | 609,616 | 617,951 |
| Accounts receivables, net of allowance for doubtful accounts of $0 and $12,313 at September 30, 2025 and December 31, 2024, respectively | 72,359 | 70,699 | 54,925 | 45,281 |
| Other receivables | 962 | 2,646 | 1,632 | 1,625 |
| Inventories | 73,288 | 75,687 | 74,403 | 70,054 |
| Prepaid expenses and other current assets | 19,907 | 22,951 | 23,674 | 18,147 |
| Total current assets | 814,331 | 785,712 | 815,970 | 848,941 |
| Property and equipment, net | 45,855 | 45,610 | 43,272 | 39,001 |
| Operating lease right-of-use assets | 19,904 | 20,314 | 20,869 | 21,608 |
| Goodwill | 2,199 | 2,200 | 2,027 | 1,946 |
| Other assets, net of allowance for doubtful accounts of $10,970 at September 30, 2025 | 64,217 | 64,613 | 63,790 | 74,760 |
| Total assets | 946,506 | 918,449 | 945,928 | 986,256 |
| Liabilities and stockholders’ equity | ||||
| Current liabilities: | ||||
| Accounts payable | 3,948 | 2,702 | 4,330 | 9,061 |
| Accrued research and development | 6,697 | 5,459 | 5,654 | 4,310 |
| Accrued liabilities | 51,889 | 65,952 | 54,292 | 61,066 |
| Convertible Notes, current portion, net of debt discount of $135 at September 30, 2025 (Note 7) | 40,073 | 40,020 | — | — |
| Other current liabilities | 4,232 | 4,097 | 4,103 | 4,197 |
| Total current liabilities | 106,839 | 118,230 | 68,379 | 78,634 |
| Convertible Notes, net of debt discount of $4,701 and $1,646 at March 31, 2025 and December 31, 2024, respectively (Note 7) | — | — | 260,507 | 223,854 |
| Convertible Notes, net of debt discount of $4,034 and $1,646 at September 30, 2025 and December 31, 2024, respectively (Note 7) | 220,966 | 220,752 | — | — |
| Long-term portion of lease liabilities | 23,985 | 24,726 | 25,521 | 26,388 |
| CEPI accrual long-term (Note 6) | 60,337 | 60,337 | 60,337 | 60,337 |
| Other long-term liabilities | 241 | 242 | 243 | 244 |
| Total liabilities | 412,368 | 424,287 | 414,987 | 389,457 |
| Stockholders’ equity: | ||||
| Preferred stock: $0.001 par value, 5,000 shares authorized at September 30, 2025 and December 31, 2024; zero shares outstanding at September 30, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 |
| Common stock: $0.001 par value, 278,000 shares authorized at September 30, 2025 and December 31, 2024; 117,364 shares and 125,450 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 117 | 117 | 124 | 125 |
| Additional paid-in capital | 1,486,947 | 1,474,046 | 1,532,835 | 1,504,671 |
| Accumulated other comprehensive income | 800 | 652 | (2,644) | (4,722) |
| Accumulated deficit | (953,726) | (980,653) | (999,374) | (903,275) |
| Total stockholders’ equity | 534,138 | 494,162 | 530,941 | 596,799 |
| Total liabilities and stockholders’ equity | 946,506 | 918,449 | 945,928 | 986,256 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.